US4185089A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunological adjuvant constituted by the p-amino-phenyl derivative of N-acetyl-muramyl-L-alanyl-D-isoglutamine
Assignee: Bpifrance Financement SA
•
Filing: 1977-10-25
•
Granted: 1980-01-22
•
Expires: 1997-10-25
Abstract
Abstract The adjuvant is 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propiony l-L-alanyl-D-isoglutamine, which compound in its beta glucoside form, corresponds with the formula <IMAGE> It is notably useful for favoring immunitory responses relative to antigens of low immunogenicity.
Inventors
- 👤 Marcel Derrien
- 👤 Edgar Lederer
- 👤 Francoise M. Audibert
- 👤 Louis Chedid
- 👤 Jean Choay
- 👤 Pierre LeFrancier
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 13:31
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61P; A61P37/00; A61P37/02; A61P37/04; C; C07; C07K; C07K9/00; C07K9/001; C07K9/005; A61K2039/555; A61K2039/55511; A61K2039/5555
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
13 words
2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine, which compound, in its β glucoside form, corresponds to the formula ##STR3##
Claim 2
Dependent Claim
13 words
2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine, which compound, in its β glucoside form, corresponds to the formula ##STR3##
Claim 3
Dependent Claim
17 words
A biological composition which comprises a pharmaceutically acceptable carrier and an effective amount of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 4
Dependent Claim
17 words
A biological composition which comprises a pharmaceutically acceptable carrier and an effective amount of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 5
Dependent Claim
18 words
The composition according to claim 2, which is an injectable emulsion containing an effective dose of the compound.
Claim 6
Dependent Claim
13 words
The composition according to claim 3, which is a water and oil emulsion.
Claim 7
Dependent Claim
15 words
The composition according to claim 3, wherein the oil is constituted by a metabolisable oil.
Claim 8
Dependent Claim
16 words
The composition according to claim 2, wherein the compound therein is associated with an immunogenic agent.
Claim 9
Dependent Claim
17 words
Vaccine composition for human use containing an immunogenic agent and an effective dose of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 10
Dependent Claim
17 words
Vaccine composition for human use containing an immunogenic agent and an effective dose of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 11
Dependent Claim
17 words
Vaccine composition for veterinary use containing an immunogenic agent and an effective dose of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 12
Dependent Claim
17 words
Vaccine composition for veterinary use containing an immunogenic agent and an effective dose of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 13
Independent Claim
22 words
A method of treating diseases in humans or animals by administrering as an immunological adjuvant, an effective amount of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 14
Independent Claim
22 words
A method of treating diseases in humans or animals by administrering as an immunological adjuvant, an effective amount of the compound 2-(p-amino-phenyl-2-acetamido-2-deoxy-3-O-D-gluco-pyranosyl)-D-propionyl-L-alanyl-D-isoglutamine.
Claim 15
Dependent Claim
10 words
The composition of claim 2 which comprises also an immunogen.
Claim 16
Dependent Claim
16 words
The composition of claim 2 which has no pyrogenicity at dosage where the compound is adjuvant.
Claim 17
Dependent Claim
12 words
The composition of claim 10 wherein the immunogen is a weak immunogen.
Claim 18
Dependent Claim
18 words
The composition of claim 2 wherein the compound is in unit dosage of about 25 to 100 mg.
Claim 19
Dependent Claim
14 words
The method of claim 9 which comprises causing an immunogenic reaction but no pyrogenicity.
References Cited (Backward Citations)
US4082735A
Cited
US4082736A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-01-21 | 1983-07-23 | 1984-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-01-21 | 1987-07-23 | 1988-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-01-21 | 1991-07-23 | 1992-01-22 | $7700.00 | Window Closed / Lapsed |